HIV感染者冠脉粥样硬化进展:心血管危险因素与非法药物使用的影响
该纵向研究从1429名无症状参与者中随机选取300例亚临床冠脉疾病患者(226例HIV感染,174例可卡因使用者),采用冠脉CTA两次评估斑块体积。结果显示HIV感染本身与斑块体积进展无独立关联,但心血管风险因素和可卡因使用年限在HIV感染者中对斑块进展影响更显著,可能解释该人群CAD加速进展。
要点
- HIV感染与冠脉斑块年进展率无显著独立关联。
- ASCVD风险百分比和可卡因使用年限增加显著提升HIV感染者斑块体积。
- HIV相关药物对斑块体积均无显著影响。
关键影像表现/征象
- HIV感染与未感染者NCP年进展率无显著差异:8.7(IQR 3.0-19.4)mm3/年 vs 4.9(IQR 1.5-18.3)mm3/年,p=0.14。
- LA-NCP年进展率两组无显著差异:0.2(IQR 0.0-1.6)mm3/年 vs 0.2(IQR 0.0-0.9)mm3/年,p=0.07。
- CP年进展率两组无显著差异:0.3(IQR 0.0-3.4)mm3/年 vs 0.1(IQR 0.0-3.2)mm3/年,p=0.30。
诊断标准与关键数值
- 多变量分析中HIV感染与NCP体积无关:-6.9mm3,CI [-32.8-19.0],p=0.60。
- HIV感染与LA-NCP体积无关:-0.1mm3,CI [-2.6-2.4],p=0.92。
- HIV感染与CP体积无关:-0.3mm3,CI [-9.3-8.6],p=0.96。
- 在HIV感染者中,ASCVD风险每增加1%及可卡因使用每增加1年,均显著增加总斑块、NCP和CP体积;在HIV未感染者中无此显著关联。
- 所有HIV相关药物对斑块体积均无显著影响(所有p>0.05)。
临床应用与阅片要点
- 阅片时注意评估HIV感染者的冠脉斑块负荷,尤其关注可卡因使用史和ASCVD风险因素。
- 对HIV感染者报告斑块体积进展时,应结合临床风险因素和药物使用情况综合解读。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess whether HIV infection directly or indirectly promotes coronary artery disease (CAD) volume progression in a longitudinal study of African Americans.
METHODS: We randomly selected 300 individuals with subclinical CAD (210 male; age: 48.0 ± 7.2 years; 226 HIV infected, 174 cocaine users) from 1429 cardiovascularly asymptomatic participants of a prospective epidemiological study between May 2004 and August 2015. Individuals underwent coronary CT angiography at two time points (mean follow-up: 4.0 ± 2.3 years). We quantified noncalcified (NCP: -100-350HU), low-attenuation noncalcified (LA-NCP: -100-30HU), and calcified (CP: ≥ 351 HU) plaque volumes. Linear mixed models were used to assess the effects of HIV infection, atherosclerotic cardiovascular disease (ASCVD) risk, and years of cocaine use on plaque volumes.
RESULTS: There was no significant difference in annual progression rates between HIV-infected and HIV-uninfected regarding NCP (8.7 [IQR: 3.0-19.4] mm3/year vs. 4.9 [IQR: 1.5-18.3] mm3/year, p = 0.14), LA-NCP (0.2 [IQR: 0.0-1.6] mm3/year vs. 0.2 [IQR: 0.0-0.9] mm3/year, p = 0.07) or CP volumes (0.3 [IQR: 0.0-3.4] mm3/year vs. 0.1 [IQR: 0.0-3.2] mm3/year, p = 0.30). Multivariately, HIV infection was not associated with NCP (-6.9mm3, CI: [-32.8-19.0], p = 0.60), LA-NCP (-0.1mm3, CI: [-2.6-2.4], p = 0.92), or CP volumes (-0.3mm3, CI: [-9.3-8.6], p = 0.96). However, each percentage of ASCVD and each year of cocaine use significantly increased total, NCP, and CP volumes among HIV-infected individuals, but not among HIV-uninfected. Importantly, none of the HIV-associated medications had any effect on plaque volumes (p > 0.05 for all).
CONCLUSIONS: The more profound adverse effect of risk factors in HIV-infected individuals may explain the accelerated progression of CAD in these people, as HIV infection was not independently associated with any coronary plaque volume.
KEY POINTS: • Human immunodeficiency virus-infected individuals may have similar subclinical coronary artery disease, as the infection is not independently associated with coronary plaque volumes. • However, cardiovascular risk factors and illicit drug use may have a more profound effect on atherosclerosis progression in those with human immunodeficiency virus infection, which may explain the accelerated progression of CAD in these people. • Nevertheless, through rigorous prevention and abstinence from illicit drugs, these individuals may experience similar cardiovascular outcomes as -uninfected individuals.
引用
- Kolossváry M, Fishman EK, Gerstenblith G, et al. Cardiovascular risk factors and illicit drug use may have a more profound effect on coronary atherosclerosis progression in people living with HIV. Eur Radiol. 2021. PMID: 33660033. doi:10.1007/s00330-021-07755-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。